Blog
CJC-1295 and Ipamorelin: Growth Hormone Secretagogue Research Peptides Explained
CJC-1295 and Ipamorelin are two of the most studied growth hormone (GH) secretagogues in the research-peptide space. In laboratory models they are frequently examined together because each compound drives the same endpoint — pulsatile GH release from the anterior pituitary — through a separate receptor. This primer explains what each peptide is, how their mechanisms differ, why investigators pair them, and how the “with DAC” and “without DAC” forms of CJC-1295 compare. Everything below is written for in-vitro and preclinical research context only.
What Are CJC-1295 and Ipamorelin?
Both molecules belong to the broad class of growth hormone secretagogues — compounds that prompt the somatotroph cells of the pituitary to secrete GH. The category splits neatly into two receptor families, and CJC-1295 and Ipamorelin sit on opposite sides of that divide.
CJC-1295 — a GHRH analog
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed on pituitary somatotrophs. Receptor activation couples to a Gs protein, raises intracellular cAMP, activates protein kinase A (PKA), and ultimately promotes GH gene transcription and vesicle release. In short, CJC-1295 mimics the body’s own GHRH signal. The research forms are listed under the CJC-1295 (with / without DAC) category.
Ipamorelin — a selective ghrelin-receptor agonist
Ipamorelin works through an entirely different door. It is a pentapeptide agonist of the ghrelin receptor (GHS-R1a). Activating GHS-R1a stimulates GH release and simultaneously dampens somatostatin’s inhibitory tone, which makes the pituitary more responsive. Among the growth-hormone-releasing peptides (GHRPs), Ipamorelin is noted in the literature for being comparatively selective: in research models it triggers GH release with little effect on cortisol or prolactin relative to older GHRPs such as GHRP-6. See the Ipamorelin category for available research vials.
Two Pathways, One Endpoint: Why Researchers Pair Them
Because CJC-1295 acts on the GHRH receptor and Ipamorelin acts on the ghrelin receptor, the two stimulate GH secretion through independent, complementary signalling cascades. Published research on GHRH-analog-plus-ghrelin-mimetic combinations reports that the paired stimulus can produce GH pulses larger than either agent alone — a synergistic rather than simply additive effect. That mechanistic synergy is why the two are so often studied as a unit, and why a ready-made CJC-1295 + Ipamorelin blend is offered alongside the single compounds.
CJC-1295 With DAC vs Without DAC
CJC-1295 is supplied in two molecular variants that behave very differently in pharmacokinetic studies:
- With DAC (Drug Affinity Complex): a reactive group lets the peptide bind serum albumin, which substantially extends its circulating half-life so GH-stimulating activity persists far longer in research models.
- Without DAC (often called Mod-GRF 1-29): no albumin-binding group, so it is cleared quickly and produces a short, sharp GH pulse that more closely resembles the body’s natural pulsatile rhythm.
Neither variant is universally “better”; the choice depends on whether a study design calls for sustained receptor exposure or brief, pulse-like stimulation.
CJC-1295 vs Ipamorelin at a Glance
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | GHRH analog | Ghrelin-receptor (GHRP) agonist |
| Receptor | GHRH receptor (GHRHR) | Ghrelin receptor (GHS-R1a) |
| Signalling | Gs → cAMP → PKA | Gq → phospholipase C → Ca²⁺ |
| Effect on somatostatin | No direct suppression | Reduces inhibitory tone |
| Selectivity note | Mimics natural GHRH pulse | Low cortisol / prolactin impact |
| Duration variants | With DAC (long) / without DAC (short) | Short-acting pentapeptide |
Handling, Reconstitution, and Verification
Like other lyophilized research peptides, CJC-1295 and Ipamorelin ship as a freeze-dried powder and are reconstituted with bacteriostatic water for in-vitro work. Storage matters: keep lyophilized vials cold and protected from light, and refrigerate after reconstitution. The guide to storing and handling research peptides covers the specifics. Before any experiment, confirm identity and purity against the Certificate of Analysis (COA), since a high-purity, correctly identified peptide is the foundation of reproducible data.
Where These Fit in the GH-Axis Toolkit
CJC-1295 and Ipamorelin are two entries in a wider family. GHRH-side analogs also include Sermorelin, while the ghrelin-receptor side includes GHRP-2 and GHRP-6. The full set lives under Growth Hormone Axis Peptides. If you are new to this area, start with What Are Research Peptides? — and for a different metabolic pathway, see the overview of GLP-1 research peptides.
Frequently Asked Questions
Do CJC-1295 and Ipamorelin act on the same receptor?
No. CJC-1295 activates the GHRH receptor; Ipamorelin activates the ghrelin (GHS-R1a) receptor. The two pathways are distinct and complementary, which is the basis for studying them together.
What does “DAC” mean?
DAC stands for Drug Affinity Complex, a modification that binds the peptide to serum albumin and extends its half-life in research models. The “without DAC” form is short-acting.
Why is Ipamorelin described as “selective”?
In published research it stimulates GH release with minimal impact on cortisol and prolactin compared with earlier GHRPs, making it a cleaner tool for isolating GH-axis effects.
Are these products for human use?
No. They are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.
